Increased glucose uptake in BrafV600E; Phd2−/− melanoma cells was significantly inhibited by FM19G11 treatment, a HIF inhibitor (Fig. 5d) or HIF-1α knockdown (Fig. 5e), which is accompanied by concomitant decreased Glut1 expression (Supplementary Fig. 6). The gene discussed is SLC2A1; the disease is melanoma.